86 A. A. KANDUTSCH AND JACK H. STIMPFLING 



Kandutsch, a. a. (i960). Cancer Res., 20, 264. 



Kandutsch, a. a. (1961). Transplant. Bull., 5, 377. 



Kandutsch, A. A., and Reinert-Wenck, U. (1957). /. exp. Med., 105, 125. 



King, E.J. (1932). Biochem.]., 26, 292. 



RosENLUND, B. (1956). Scand.J. din. Lah. Invest., 8, 177. 



Smith, J. T., Junckes, A. J., Barak, A. J., and Thomas, L. E. (1957). Exp. Cell 



Res., 13, 96. 

 Snell, G. D. (1952). ]. nat. Cancer Inst., 13, 719. 

 Snell, G. D. (1957). Ann. Rev. Microbiol, 11, 439. 

 Stimpfling, J. H. (1961). Transplant. Bull., 27, 109. 

 Warren, L. (1959). J. hiol. Chem., 234, 1971. 

 Winzler, R. J. (1955). In Methods of Biochemical Analysis, 2, 290, ed. 



Glick, D. New York: Interscience. 



DISCUSSION 



Medawar: Do you know that your preparation doesn't sensitize 

 against, for example, skin grafts ? I ask this because sarcoma I is, as I 

 understand it, an easily " enhanceable " tumour. Secondly, do you 

 attribute your results to the formation of humoral antibodies — that is to 

 say, can you passively transfer your effect with serum? This would 

 definitely make it an enhancement phenomenon. 



Kandutsch: I can't answer either of these questions affirmatively with 

 regard to my purest preparations. However, I think Dr. Haskova has 

 found that preparations similar to those I used, and which I expect 

 would produce the effects that I find, do also produce sensitization to a 

 skin graft. We haven't had enough material yet to investigate this fully. 

 With regard to the enhancement phenomenon, we have not tried to 

 transfer this tumour-promoting effect with serum from animals 

 immunized with the purest material but the test has always responded 

 to antiserum from animals immunized with less pure preparations up to 

 this point, and I had not thought it really necessary to try it again. 



Davies: I think Gorer said that sarcoma I lacked several of the H-2 

 antigens of A mice. I wondered if that might affect your system. 



Amos: It depends on the sarcoma I ; there are great differences between 

 sublines of sarcoma I. 



Kandutsch: We have used this ascites form for several years, and it has 

 become increasingly malignant. One has to use quite a lot in order to 



